The microbial production of natural products has been traditionally accomplished in a single organism engineered to accommodate target biosynthetic pathways. Often times, such approaches result in large metabolic burdens as key cofactors, precursor metabolites and energy are channeled to pathways of structurally complex chemicals. Recently, modular co-culture engineering has emerged as a new approach to efficiently conduct heterologous biosynthesis and greatly enhance the production of natural products. This review highlights recent advances that leverage Escherichia coli-based modular co-culture engineering for making natural products. Potential future perspectives for studies in this promising field are addressed as well.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.copbio.2019.09.004 | DOI Listing |
Integr Environ Assess Manag
January 2025
Department of Civil and Environmental Engineering, Florida State University, Tallahassee, FL, United States.
The growing concern over environmental pollution has spurred extensive research into various contaminants impacting ecosystems and human health. Emerging contaminants (ECs), including pharmaceuticals, personal care products, endocrine-disrupting chemicals, nanomaterials, and microplastics, have garnered significant attention due to their persistence, bioaccumulation, and toxicity. This study presents a comprehensive bibliometric analysis of EC research, aiming to detail the research landscape, highlight significant contributions, and identify influential researchers and pivotal studies.
View Article and Find Full Text PDFJ Nat Prod
January 2025
Pharmacognosy Institute and Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois 60612, United States.
To date, quantitative analysis of proanthocyanidin (PAC) containing materials including plant extracts and fractions depends on colorimetric assays or phloroglucinolysis/thiolysis combined with UV-HPLC analysis. Such assays are of limited accuracy, particularly lack specificity, require extensive sample preparation and degradation, and need appropriate physical reference standards. To address this analytical challenge and toward our broader goal of developing new plant-sourced biomaterials that chemically and mechanically modulate the properties of dental tissue for clinical interventions, we have characterized 12 different PAC DESIGNER (Depletion and Enrichment of Select Ingredients Generating Normalized Extract Resources) materials.
View Article and Find Full Text PDFToxicol Sci
January 2025
Department of Pharmacology, University of the Free State, Bloemfontein, 9300, South Africa.
Medicinal plants are products from natural sources that have found relevance in medicine for several decades. They are rich in bioactive compounds; thus, they are widely used to treat different ailments globally. Medicinal plants have provided hope for the health care industry as most are used to synthesize modern medicines currently used in the treatment of various diseases.
View Article and Find Full Text PDFACS Infect Dis
January 2025
Pharmaceutical Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Pilani, Vidya Vihar 333031, (RJ) India.
Antimicrobial drug resistance is a significant global health challenge, causing hundreds of thousands of deaths annually and severely impacting healthcare systems worldwide. Several reported antimicrobial compounds have a guanidine motif, as the positive charge on guanidine promotes cell lysis. Therefore, pyrrole- and indole-based allylidene hydrazine carboximidamide derivatives with guanidine motifs are proposed as antimicrobial agents that mimic cationic antimicrobial peptides (CAMPs).
View Article and Find Full Text PDFNeurology
January 2025
The Dubowitz Neuromuscular Centre, Developmental Neurosciences Department, University College London, Great Ormond Street Institute of Child Health, United Kingdom.
Background And Objectives: Safety and efficacy of IV onasemnogene abeparvovec has been demonstrated for patients with spinal muscular atrophy (SMA) weighing <8.5 kg. SMART was the first clinical trial to evaluate onasemnogene abeparvovec for participants weighing 8.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!